The parasitic worm-derived immunomodulator, ES-62 and its drug-like small molecule analogues exhibit therapeutic potential in a model of chronic asthma

J. C. Coltherd, D. T. Rodgers, R. E. Lawrie, L. Al-Riyami, C. J. Suckling, W. Harnett, M. M. Harnett

Research output: Contribution to journalArticle

14 Citations (Scopus)
101 Downloads (Pure)

Abstract

Chronic asthma is associated with persistent lung inflammation and long-term remodelling of the airways that have proved refractory to conventional treatments such as steroids, despite their efficacy in controlling acute airway contraction and bronchial inflammation. As its recent dramatic increase in industrialised countries has not been mirrored in developing regions, it has been suggested that helminth infection may protect humans against developing asthma. Consistent with this, ES-62, an immunomodulator secreted by the parasitic worm Acanthocheilonema viteae, can prevent pathology associated with chronic asthma (cellular infiltration of the lungs, particularly neutrophils and mast cells, mucus hyper-production and airway thickening) in an experimental mouse model. Importantly, ES-62 can act even after airway remodelling has been established, arresting pathogenesis and ameliorating the inflammatory flares resulting from repeated exposure to allergen that are a debilitating feature of severe chronic asthma. Moreover, two chemical analogues of ES-62, 11a and 12b mimic its therapeutic actions in restoring levels of regulatory B cells and suppressing neutrophil and mast cell responses. These studies therefore provide a platform for developing ES-62-based drugs, with compounds 11a and 12b representing the first step in the development of a novel class of drugs to combat the hitherto intractable disorder of chronic asthma.

Original languageEnglish
Article number19224
Number of pages14
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - 14 Jan 2016

Fingerprint

Helminths
Immunologic Factors
Asthma
Molecules
Airway Remodeling
Pharmaceutical Preparations
Mast Cells
Acanthocheilonema
Regulatory B-Lymphocytes
Neutrophils
Pathology
Therapeutics
Infiltration
Refractory materials
Allergens
Mucus
Developed Countries
Steroids
Cells
Pneumonia

Keywords

  • asthma
  • therapeutics
  • prevention
  • Acanthocheilonema viteae
  • allergen

Cite this

@article{02382b15f73d4d729f27d6f8bf37c04b,
title = "The parasitic worm-derived immunomodulator, ES-62 and its drug-like small molecule analogues exhibit therapeutic potential in a model of chronic asthma",
abstract = "Chronic asthma is associated with persistent lung inflammation and long-term remodelling of the airways that have proved refractory to conventional treatments such as steroids, despite their efficacy in controlling acute airway contraction and bronchial inflammation. As its recent dramatic increase in industrialised countries has not been mirrored in developing regions, it has been suggested that helminth infection may protect humans against developing asthma. Consistent with this, ES-62, an immunomodulator secreted by the parasitic worm Acanthocheilonema viteae, can prevent pathology associated with chronic asthma (cellular infiltration of the lungs, particularly neutrophils and mast cells, mucus hyper-production and airway thickening) in an experimental mouse model. Importantly, ES-62 can act even after airway remodelling has been established, arresting pathogenesis and ameliorating the inflammatory flares resulting from repeated exposure to allergen that are a debilitating feature of severe chronic asthma. Moreover, two chemical analogues of ES-62, 11a and 12b mimic its therapeutic actions in restoring levels of regulatory B cells and suppressing neutrophil and mast cell responses. These studies therefore provide a platform for developing ES-62-based drugs, with compounds 11a and 12b representing the first step in the development of a novel class of drugs to combat the hitherto intractable disorder of chronic asthma.",
keywords = "asthma, therapeutics, prevention, Acanthocheilonema viteae, allergen",
author = "Coltherd, {J. C.} and Rodgers, {D. T.} and Lawrie, {R. E.} and L. Al-Riyami and Suckling, {C. J.} and W. Harnett and Harnett, {M. M.}",
year = "2016",
month = "1",
day = "14",
doi = "10.1038/srep19224",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",

}

The parasitic worm-derived immunomodulator, ES-62 and its drug-like small molecule analogues exhibit therapeutic potential in a model of chronic asthma. / Coltherd, J. C.; Rodgers, D. T.; Lawrie, R. E.; Al-Riyami, L.; Suckling, C. J.; Harnett, W.; Harnett, M. M.

In: Scientific Reports, Vol. 6, 19224, 14.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The parasitic worm-derived immunomodulator, ES-62 and its drug-like small molecule analogues exhibit therapeutic potential in a model of chronic asthma

AU - Coltherd, J. C.

AU - Rodgers, D. T.

AU - Lawrie, R. E.

AU - Al-Riyami, L.

AU - Suckling, C. J.

AU - Harnett, W.

AU - Harnett, M. M.

PY - 2016/1/14

Y1 - 2016/1/14

N2 - Chronic asthma is associated with persistent lung inflammation and long-term remodelling of the airways that have proved refractory to conventional treatments such as steroids, despite their efficacy in controlling acute airway contraction and bronchial inflammation. As its recent dramatic increase in industrialised countries has not been mirrored in developing regions, it has been suggested that helminth infection may protect humans against developing asthma. Consistent with this, ES-62, an immunomodulator secreted by the parasitic worm Acanthocheilonema viteae, can prevent pathology associated with chronic asthma (cellular infiltration of the lungs, particularly neutrophils and mast cells, mucus hyper-production and airway thickening) in an experimental mouse model. Importantly, ES-62 can act even after airway remodelling has been established, arresting pathogenesis and ameliorating the inflammatory flares resulting from repeated exposure to allergen that are a debilitating feature of severe chronic asthma. Moreover, two chemical analogues of ES-62, 11a and 12b mimic its therapeutic actions in restoring levels of regulatory B cells and suppressing neutrophil and mast cell responses. These studies therefore provide a platform for developing ES-62-based drugs, with compounds 11a and 12b representing the first step in the development of a novel class of drugs to combat the hitherto intractable disorder of chronic asthma.

AB - Chronic asthma is associated with persistent lung inflammation and long-term remodelling of the airways that have proved refractory to conventional treatments such as steroids, despite their efficacy in controlling acute airway contraction and bronchial inflammation. As its recent dramatic increase in industrialised countries has not been mirrored in developing regions, it has been suggested that helminth infection may protect humans against developing asthma. Consistent with this, ES-62, an immunomodulator secreted by the parasitic worm Acanthocheilonema viteae, can prevent pathology associated with chronic asthma (cellular infiltration of the lungs, particularly neutrophils and mast cells, mucus hyper-production and airway thickening) in an experimental mouse model. Importantly, ES-62 can act even after airway remodelling has been established, arresting pathogenesis and ameliorating the inflammatory flares resulting from repeated exposure to allergen that are a debilitating feature of severe chronic asthma. Moreover, two chemical analogues of ES-62, 11a and 12b mimic its therapeutic actions in restoring levels of regulatory B cells and suppressing neutrophil and mast cell responses. These studies therefore provide a platform for developing ES-62-based drugs, with compounds 11a and 12b representing the first step in the development of a novel class of drugs to combat the hitherto intractable disorder of chronic asthma.

KW - asthma

KW - therapeutics

KW - prevention

KW - Acanthocheilonema viteae

KW - allergen

UR - http://www.scopus.com/inward/record.url?scp=84954490928&partnerID=8YFLogxK

UR - http://www.nature.com/srep/

U2 - 10.1038/srep19224

DO - 10.1038/srep19224

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 19224

ER -